SCO-Spondin-Derived Peptide NX210 Promotes Functional Recovery after Spinal Cord Injury in Mice
Journal of Neurotrauma · 01.12.2025 · 42 (23-24) · 2163-2177
DOI: 10.1177/08977151251359983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurotrauma, online erschienen am 10.01.2026. Verfasst von Theresa C Sutherland und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center, Bryan, Texas, USA. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Recovery of Function, Thrombospondins, Peptide Fragments. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bryon Riesch Paralysis Foundation.
Abstract (Originalsprache)
Spinal cord injury (SCI) represents a major public health issue, as the consequences are often irreversible with no treatment currently available. This results in a growing population living with long-lasting motor, sensory, and/or autonomic impairments directly related to their SCI. Here, we have evaluated the therapeutic potential of a thrombospondin repeats peptide analogue, named NX210, in a mouse hemisection model of SCI. Adult female mice were subjected to a thoracic level 8 dorsal hemisection, and treated with intraperitoneal injections of NX210 starting at 4 h post-injury and then twice a week at 4, 8, or 16 mg/kg. Hind limb motor function was assessed once a week for 10 weeks post-injury using the Basso Mouse Scale (BMS) score and sub-score, the rotarod, and the activity chamber tests. Mice were then sacrificed, and the spinal cords were collected for immunohistochemistry. Interestingly, NX210 improved functional recovery (BMS score and sub-score, latency to fall from the rotarod, spontaneous locomotor activity) with rapid rises in function that were maintained throughout the 10-week study. This was accompanied by a reduction of nociceptive reactivity assessed by the tail flick test. NX210 treatment also increased myelin basic protein and reduced neuron/glial antigen 2 at the injury site 10 weeks post-injury while no significant effects were observed on lesion size, inflammation, and neuron survival. Overall, this study highlights a potential new therapeutic strategy to promote repair and decrease long-lasting functional impairments after SCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center, Bryan, Texas, USA.
- Axoltis Pharma, Lyon, France.
- Godfrin Life-Sciences, Caluire-et-Cuire, France.
ORCID-Profile: Ashley J Douthitt, Cédric G Geoffroy
Förderung
- Bryon Riesch Paralysis Foundation
Zitieren
APA
Sutherland, T. C., Lemarchant, S., Douthitt, A. J., Lopez, A. H., Kuhlman, L., Horvat, D., Sefiani, A., Johnson, S. M., Hassan, Z., Bachir, N., Dundumulla, R., Hook, M., Godfrin, Y., & Geoffroy, C. G. (2025). SCO-Spondin-Derived Peptide NX210 Promotes Functional Recovery after Spinal Cord Injury in Mice. Journal of Neurotrauma, 42(23-24), 2163-2177. https://doi.org/10.1177/08977151251359983
Vancouver
Sutherland TC, Lemarchant S, Douthitt AJ, Lopez AH, Kuhlman L, Horvat D, et al. SCO-Spondin-Derived Peptide NX210 Promotes Functional Recovery after Spinal Cord Injury in Mice. Journal of Neurotrauma. 2025;42(23-24):2163-2177. doi:10.1177/08977151251359983
BibTeX
@article{Sutherland2025,
author = {Sutherland, Theresa C and Lemarchant, Sighild and Douthitt, Ashley J and Lopez, Alexandra H and Kuhlman, Lily and Horvat, Darijana and Sefiani, Arthur and Johnson, Sydney M and Hassan, Zoha and Bachir, Natalie and Dundumulla, Ravali and Hook, Michelle and Godfrin, Yann and Geoffroy, Cédric G},
title = {SCO-Spondin-Derived Peptide NX210 Promotes Functional Recovery after Spinal Cord Injury in Mice},
journal = {Journal of Neurotrauma},
year = {2025},
volume = {42},
number = {23-24},
pages = {2163--2177},
doi = {10.1177/08977151251359983}
}
EUVIMED